{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:53:06Z","timestamp":1789084386286,"version":"build-2803163510"},"reference-count":200,"publisher":"Cold Spring Harbor Laboratory","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cold Spring Harb Perspect Med"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1101\/cshperspect.a031286","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T01:35:12Z","timestamp":1513042512000},"page":"a031286","source":"Crossref","is-referenced-by-count":47,"title":["Multiple Myeloma and Bone: The Fatal Interaction"],"prefix":"10.1101","volume":"8","author":[{"given":"Silvia","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"246","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"2018091410385550000_8.8.a031286.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-4666(03)00106-6"},{"key":"2018091410385550000_8.8.a031286.2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 in the development of osteolytic lesions in multiple myeloma","volume":"100","year":"2002","journal-title":"Blood"},{"key":"2018091410385550000_8.8.a031286.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3839"},{"key":"2018091410385550000_8.8.a031286.4","first-page":"172458","article-title":"Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling","volume":"2015","year":"2015","journal-title":"Biomed Res Int"},{"key":"2018091410385550000_8.8.a031286.5","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0242-T"},{"key":"2018091410385550000_8.8.a031286.6","doi-asserted-by":"publisher","DOI":"10.1038\/36593"},{"key":"2018091410385550000_8.8.a031286.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.07.004"},{"key":"2018091410385550000_8.8.a031286.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0356-8"},{"key":"2018091410385550000_8.8.a031286.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3074"},{"key":"2018091410385550000_8.8.a031286.10","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12035"},{"key":"2018091410385550000_8.8.a031286.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2151"},{"key":"2018091410385550000_8.8.a031286.12","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.29160","article-title":"Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"2018091410385550000_8.8.a031286.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1924-9"},{"key":"2018091410385550000_8.8.a031286.14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.190"},{"key":"2018091410385550000_8.8.a031286.15","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1038\/bcj.2016.118","article-title":"A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival","volume":"6","year":"2016","journal-title":"Blood Cancer J"},{"key":"2018091410385550000_8.8.a031286.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2008.03.018"},{"key":"2018091410385550000_8.8.a031286.17","doi-asserted-by":"publisher","DOI":"10.2302\/kjm.54.127"},{"key":"2018091410385550000_8.8.a031286.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658"},{"key":"2018091410385550000_8.8.a031286.19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1749-6632.2009.05304.x","article-title":"The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3","volume":"1192","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"2018091410385550000_8.8.a031286.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06196.x"},{"key":"2018091410385550000_8.8.a031286.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237628"},{"key":"2018091410385550000_8.8.a031286.22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jbmr.2022","article-title":"PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression","volume":"29","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2018091410385550000_8.8.a031286.23","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.71"},{"key":"2018091410385550000_8.8.a031286.24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-\u03b1 is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","year":"2000","journal-title":"Blood"},{"key":"2018091410385550000_8.8.a031286.25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200113116"},{"key":"2018091410385550000_8.8.a031286.26","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1038\/leu.2009.136","article-title":"Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients","volume":"23","year":"2009","journal-title":"Leukemia"},{"key":"2018091410385550000_8.8.a031286.27","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.22"},{"key":"2018091410385550000_8.8.a031286.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607948"},{"key":"2018091410385550000_8.8.a031286.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3534"},{"key":"2018091410385550000_8.8.a031286.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026627"},{"key":"2018091410385550000_8.8.a031286.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384784"},{"key":"2018091410385550000_8.8.a031286.32","first-page":"82","article-title":"Cross-talk between T cells and osteoclasts in bone resorption","volume":"1","year":"2012","journal-title":"Bonekey Rep"},{"key":"2018091410385550000_8.8.a031286.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01599.x"},{"key":"2018091410385550000_8.8.a031286.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1703"},{"key":"2018091410385550000_8.8.a031286.35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.152"},{"key":"2018091410385550000_8.8.a031286.36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","year":"2017","journal-title":"Bone"},{"key":"2018091410385550000_8.8.a031286.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143222"},{"key":"2018091410385550000_8.8.a031286.38","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.29"},{"key":"2018091410385550000_8.8.a031286.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-346775"},{"key":"2018091410385550000_8.8.a031286.40","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1: A potential therapeutic strategy for myeloma bone disease","volume":"31","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2018091410385550000_8.8.a031286.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00323.x"},{"key":"2018091410385550000_8.8.a031286.42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1080"},{"key":"2018091410385550000_8.8.a031286.43","first-page":"245247","article-title":"Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study","volume":"2014","year":"2014","journal-title":"Biomed Res Int"},{"key":"2018091410385550000_8.8.a031286.44","doi-asserted-by":"publisher","DOI":"10.1007\/s10266-012-0070-5"},{"key":"2018091410385550000_8.8.a031286.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330407"},{"key":"2018091410385550000_8.8.a031286.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.483"},{"key":"2018091410385550000_8.8.a031286.47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191577"},{"key":"2018091410385550000_8.8.a031286.48","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.65"},{"key":"2018091410385550000_8.8.a031286.49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M500608200"},{"key":"2018091410385550000_8.8.a031286.50","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.52"},{"key":"2018091410385550000_8.8.a031286.51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3527"},{"key":"2018091410385550000_8.8.a031286.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.03.015"},{"key":"2018091410385550000_8.8.a031286.53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4986"},{"key":"2018091410385550000_8.8.a031286.54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-026112"},{"key":"2018091410385550000_8.8.a031286.55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059188"},{"key":"2018091410385550000_8.8.a031286.56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4666"},{"key":"2018091410385550000_8.8.a031286.57","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-011-0072-9"},{"key":"2018091410385550000_8.8.a031286.58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.381"},{"key":"2018091410385550000_8.8.a031286.59","doi-asserted-by":"publisher","DOI":"10.2174\/156802610791561237"},{"key":"2018091410385550000_8.8.a031286.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2005.02.017"},{"key":"2018091410385550000_8.8.a031286.61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118947"},{"key":"2018091410385550000_8.8.a031286.62","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0220"},{"key":"2018091410385550000_8.8.a031286.63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3349"},{"key":"2018091410385550000_8.8.a031286.64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2664"},{"key":"2018091410385550000_8.8.a031286.65","first-page":"583439","article-title":"Multiple myeloma: A review of imaging features and radiological techniques","volume":"2011","year":"2011","journal-title":"Bone Marrow Res"},{"key":"2018091410385550000_8.8.a031286.66","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor \u03baB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2018091410385550000_8.8.a031286.67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"2018091410385550000_8.8.a031286.68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3545"},{"key":"2018091410385550000_8.8.a031286.69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1874"},{"key":"2018091410385550000_8.8.a031286.70","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn266"},{"key":"2018091410385550000_8.8.a031286.71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173948"},{"key":"2018091410385550000_8.8.a031286.72","doi-asserted-by":"publisher","DOI":"10.1007\/s001090100226"},{"key":"2018091410385550000_8.8.a031286.73","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(99)00162-3"},{"key":"2018091410385550000_8.8.a031286.74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438606"},{"key":"2018091410385550000_8.8.a031286.75","unstructured":"Howlader N , Noone AM , Krapcho M , Miller D , Bishop K , Altekruse SF , Kosary CL , Yu M , Ruhl J , Tatalovich Z , Mariotto A , 2016. SEER Cancer Statistics Review, 1975\u20132013. National Cancer Institute, Bethesda, MD."},{"key":"2018091410385550000_8.8.a031286.76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.3540"},{"key":"2018091410385550000_8.8.a031286.77","doi-asserted-by":"publisher","DOI":"10.1210\/en.142.4.1419"},{"key":"2018091410385550000_8.8.a031286.78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13148-017-0319-5","article-title":"Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma","volume":"9","year":"2017","journal-title":"Clin Epigenetics"},{"key":"2018091410385550000_8.8.a031286.79","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","year":"2014","journal-title":"Br J Haematol"},{"key":"2018091410385550000_8.8.a031286.80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1053-03"},{"key":"2018091410385550000_8.8.a031286.81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01065.x"},{"key":"2018091410385550000_8.8.a031286.82","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026526703898"},{"key":"2018091410385550000_8.8.a031286.83","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bjh.13020","article-title":"The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: Defining the stromal defect in myeloma","volume":"167","year":"2014","journal-title":"Br J Haematol"},{"key":"2018091410385550000_8.8.a031286.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2010.04.003"},{"key":"2018091410385550000_8.8.a031286.85","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2002.01314.x"},{"key":"2018091410385550000_8.8.a031286.86","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01428-09"},{"key":"2018091410385550000_8.8.a031286.87","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0254-1_12"},{"key":"2018091410385550000_8.8.a031286.88","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403084"},{"key":"2018091410385550000_8.8.a031286.89","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403285"},{"key":"2018091410385550000_8.8.a031286.90","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1752-1947-8-299","article-title":"Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: A case report","volume":"8","year":"2014","journal-title":"J Med Case Rep"},{"key":"2018091410385550000_8.8.a031286.91","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28267"},{"key":"2018091410385550000_8.8.a031286.92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"2018091410385550000_8.8.a031286.93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"2018091410385550000_8.8.a031286.94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1269"},{"key":"2018091410385550000_8.8.a031286.95","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"2018091410385550000_8.8.a031286.96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1992"},{"key":"2018091410385550000_8.8.a031286.97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2383"},{"key":"2018091410385550000_8.8.a031286.98","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2007.0074"},{"key":"2018091410385550000_8.8.a031286.99","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328302c7f4"},{"key":"2018091410385550000_8.8.a031286.100","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46134"},{"key":"2018091410385550000_8.8.a031286.101","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-006-9033-z"},{"key":"2018091410385550000_8.8.a031286.102","first-page":"832704","article-title":"The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy","volume":"2014","year":"2014","journal-title":"Biomed Res Int"},{"key":"2018091410385550000_8.8.a031286.103","doi-asserted-by":"crossref","first-page":"34329","DOI":"10.18632\/oncotarget.6020","article-title":"Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"2018091410385550000_8.8.a031286.104","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087809"},{"key":"2018091410385550000_8.8.a031286.105","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0038"},{"key":"2018091410385550000_8.8.a031286.106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.01.370"},{"key":"2018091410385550000_8.8.a031286.107","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01485.x"},{"key":"2018091410385550000_8.8.a031286.108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3385"},{"key":"2018091410385550000_8.8.a031286.109","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-198"},{"key":"2018091410385550000_8.8.a031286.110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-773341"},{"key":"2018091410385550000_8.8.a031286.111","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.112"},{"key":"2018091410385550000_8.8.a031286.112","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041131"},{"key":"2018091410385550000_8.8.a031286.113","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-006-9038-6"},{"key":"2018091410385550000_8.8.a031286.114","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2015.1052928"},{"key":"2018091410385550000_8.8.a031286.115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.4079"},{"key":"2018091410385550000_8.8.a031286.116","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13577"},{"key":"2018091410385550000_8.8.a031286.117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0236"},{"key":"2018091410385550000_8.8.a031286.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2006.12.002"},{"key":"2018091410385550000_8.8.a031286.119","doi-asserted-by":"publisher","DOI":"10.1038\/nrc867"},{"key":"2018091410385550000_8.8.a031286.120","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0024"},{"key":"2018091410385550000_8.8.a031286.121","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.9788"},{"key":"2018091410385550000_8.8.a031286.122","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2452"},{"key":"2018091410385550000_8.8.a031286.123","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(03)00841-2"},{"key":"2018091410385550000_8.8.a031286.124","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2489"},{"key":"2018091410385550000_8.8.a031286.125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283895"},{"key":"2018091410385550000_8.8.a031286.126","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.11.015"},{"key":"2018091410385550000_8.8.a031286.127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3905"},{"key":"2018091410385550000_8.8.a031286.128","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast","volume":"8","year":"1889","journal-title":"Cancer Metastasis Rev"},{"key":"2018091410385550000_8.8.a031286.129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0431"},{"key":"2018091410385550000_8.8.a031286.130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711263105"},{"key":"2018091410385550000_8.8.a031286.131","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201394498"},{"key":"2018091410385550000_8.8.a031286.132","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.642090"},{"key":"2018091410385550000_8.8.a031286.133","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0225"},{"key":"2018091410385550000_8.8.a031286.134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246660"},{"key":"2018091410385550000_8.8.a031286.135","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03654.x"},{"key":"2018091410385550000_8.8.a031286.136","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1038\/bcj.2015.96","article-title":"Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial","volume":"6","year":"2016","journal-title":"Blood Cancer J"},{"key":"2018091410385550000_8.8.a031286.137","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.clml.2017.03.047","article-title":"An international, randomized, double blind trial comparing denosumab with zoledronic acid (ZA) for the treatment of bone disease in patients (pts) with newly diagnosed multiple myeloma","volume":"17","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2018091410385550000_8.8.a031286.138","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2018091410385550000_8.8.a031286.139","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2050-7771-2-8","article-title":"Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients","volume":"2","year":"2014","journal-title":"Biomark Res"},{"key":"2018091410385550000_8.8.a031286.140","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66517"},{"key":"2018091410385550000_8.8.a031286.141","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(99)00061-2"},{"key":"2018091410385550000_8.8.a031286.142","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.11.1921"},{"key":"2018091410385550000_8.8.a031286.143","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"2018091410385550000_8.8.a031286.144","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation-2008.1.313","article-title":"Skeletal imaging and management of bone disease","volume":"2008","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2018091410385550000_8.8.a031286.145","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.336"},{"key":"2018091410385550000_8.8.a031286.146","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","year":"2010","journal-title":"J Cell Biochem"},{"key":"2018091410385550000_8.8.a031286.147","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.06.016"},{"key":"2018091410385550000_8.8.a031286.148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.09.002"},{"key":"2018091410385550000_8.8.a031286.149","doi-asserted-by":"crossref","unstructured":"Rosen CJ . 2013. Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley-Blackwell, Ames, IA.","DOI":"10.1002\/9781118453926"},{"key":"2018091410385550000_8.8.a031286.150","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/onc.2016.309","article-title":"Non-canonical NF\u03baB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NF-\u03baB pathway","volume":"36","year":"2017","journal-title":"Oncogene"},{"key":"2018091410385550000_8.8.a031286.151","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22991"},{"key":"2018091410385550000_8.8.a031286.152","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2280"},{"key":"2018091410385550000_8.8.a031286.153","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1200\/JCO.2002.20.1.353","article-title":"Human bone marrow myeloma cells express RANKL","volume":"20","year":"2002","journal-title":"J Clin Oncol"},{"key":"2018091410385550000_8.8.a031286.154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0148"},{"key":"2018091410385550000_8.8.a031286.155","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"2018091410385550000_8.8.a031286.156","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.385"},{"key":"2018091410385550000_8.8.a031286.157","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1182\/blood.V128.22.4410.4410","article-title":"p62\u2013ZZ domain signaling inhibition rescues MM-induced epigenetic repression at the Runx2 promoter and allows osteoblast differentiation of MM patient pre-osteoblasts in vitro","volume":"128","year":"2016","journal-title":"Blood"},{"key":"2018091410385550000_8.8.a031286.158","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05084.x"},{"key":"2018091410385550000_8.8.a031286.159","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0219"},{"key":"2018091410385550000_8.8.a031286.160","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"2018091410385550000_8.8.a031286.161","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/fon.12.76","article-title":"The multifaceted actions of PTHrP in skeletal metastasis","volume":"8","year":"2012","journal-title":"Future Oncol"},{"key":"2018091410385550000_8.8.a031286.162","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.02883"},{"key":"2018091410385550000_8.8.a031286.163","first-page":"1779","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2018091410385550000_8.8.a031286.164","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood.V128.22.4439.4439","article-title":"Regulation of osteoblast function in myeloma bone disease by semaphorin 4D","volume":"128","year":"2016","journal-title":"Blood"},{"key":"2018091410385550000_8.8.a031286.165","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1647"},{"key":"2018091410385550000_8.8.a031286.166","first-page":"495","article-title":"Vitamin D endocrine system and osteoclasts","volume":"3","year":"2014","journal-title":"Bonekey Rep"},{"key":"2018091410385550000_8.8.a031286.167","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2258"},{"key":"2018091410385550000_8.8.a031286.168","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.229"},{"key":"2018091410385550000_8.8.a031286.169","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0380"},{"key":"2018091410385550000_8.8.a031286.170","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"2018091410385550000_8.8.a031286.171","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn796"},{"key":"2018091410385550000_8.8.a031286.172","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27342"},{"key":"2018091410385550000_8.8.a031286.173","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V120.21.1819.1819","article-title":"Semaphorin-4D and plexin-B1 are elevated in multiple myeloma microenvironment and possibly contribute in the development of lytic bone disease","volume":"120","year":"2012","journal-title":"Blood"},{"key":"2018091410385550000_8.8.a031286.174","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"2018091410385550000_8.8.a031286.175","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0136772100"},{"key":"2018091410385550000_8.8.a031286.176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.027"},{"key":"2018091410385550000_8.8.a031286.177","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jbmr.2741","article-title":"The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: A new function for proteasome inhibitors","volume":"31","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2018091410385550000_8.8.a031286.178","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22907"},{"key":"2018091410385550000_8.8.a031286.179","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04040.x"},{"key":"2018091410385550000_8.8.a031286.180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-093294"},{"key":"2018091410385550000_8.8.a031286.181","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911929107"},{"key":"2018091410385550000_8.8.a031286.182","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.43"},{"key":"2018091410385550000_8.8.a031286.183","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.02.005"},{"key":"2018091410385550000_8.8.a031286.184","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32819f820b"},{"key":"2018091410385550000_8.8.a031286.185","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4361"},{"key":"2018091410385550000_8.8.a031286.186","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.11.007"},{"key":"2018091410385550000_8.8.a031286.187","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-562439"},{"key":"2018091410385550000_8.8.a031286.188","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215687"},{"key":"2018091410385550000_8.8.a031286.189","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.40.25190"},{"key":"2018091410385550000_8.8.a031286.190","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1547"},{"key":"2018091410385550000_8.8.a031286.191","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03257.x"},{"key":"2018091410385550000_8.8.a031286.192","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1131"},{"key":"2018091410385550000_8.8.a031286.193","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","year":"2006","journal-title":"Haematologica"},{"key":"2018091410385550000_8.8.a031286.194","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047712"},{"key":"2018091410385550000_8.8.a031286.195","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.7.3597"},{"key":"2018091410385550000_8.8.a031286.196","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1182\/blood.V126.23.4241.4241","article-title":"Phase 1 dose-escalation study of sotatercept (ACE-011) in combination with lenalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"126","year":"2015","journal-title":"Blood"},{"key":"2018091410385550000_8.8.a031286.197","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05733.x"},{"key":"2018091410385550000_8.8.a031286.198","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01602.x"},{"key":"2018091410385550000_8.8.a031286.199","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2013.08.002","article-title":"Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention","volume":"27","year":"2013","journal-title":"Blood Rev"},{"key":"2018091410385550000_8.8.a031286.200","doi-asserted-by":"publisher","DOI":"10.1038\/nri2742"}],"container-title":["Cold Spring Harbor Perspectives in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/cshperspect.a031286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T16:39:59Z","timestamp":1719679199000},"score":1,"resource":{"primary":{"URL":"http:\/\/perspectivesinmedicine.cshlp.org\/lookup\/doi\/10.1101\/cshperspect.a031286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":200,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1101\/cshperspect.a031286"],"URL":"https:\/\/doi.org\/10.1101\/cshperspect.a031286","relation":{},"ISSN":["2157-1422"],"issn-type":[{"value":"2157-1422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]}}}